Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes
- Written by PR Newswire
![]() |
GAITHERSBURG, Md., Dec. 16, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the pricing of an offering of $150 million aggregate principal amount of its 5.00% convertible senior notes due 2027 (the...
Read more: Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes















